Expression of E2F‐4 in invasive breast carcinomas is associated with poor prognosis
- 21 June 2004
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 203 (3), 754-761
- https://doi.org/10.1002/path.1573
Abstract
The E2F family of transcription factors plays a key role in the control of cellular proliferation and apoptosis. Some family members act as oncogenes and others act as tumour suppressor genes (TSGs), behaviour which appears to be tissue‐specific. E2F‐4 is a member of the E2F family, located at chromosome band 16q22.1, that shows frequent deletion in breast cancer, suggesting that it may function as a TSG in breast carcinogenesis. In the present study, the expression of E2F‐4 was assessed immunohistochemically on paraffin wax sections from 265 breast carcinomas and expression was compared with both clinicopathological variables and disease outcome in an attempt to identify its possible role as a TSG and to assess its prognostic value, if any, in breast cancer. E2F‐4 protein expression was detected in the nuclei and in the cytoplasm of normal and malignant breast epithelial cells. In the malignant tissues, no significant loss or decrease of expression was seen in association with any specific tumour type. There was a correlation between increased nuclear expression of E2F‐4 and indicators of poor prognosis including larger tumour size (p = 0.000), grade 3 lesions (p = 0.033), lymph node stage (p = 0.037), and poorer Nottingham prognostic index group (p = 0.003). Increased immunoreactivity was also seen in association with the development of recurrent disease (p = 0.004), distant metastasis (p = 0.001), and poorer outcome including poorer overall survival time (p = 0.002) and shorter disease‐free interval (p = 0.001). In multivariate analysis, E2F‐4 was of independent prognostic significance along with grade and lymph node stage. These results suggest that E2F‐4 may play a role in breast cancer progression and that increased nuclear expression is associated with more advanced tumours with poor outcomes. E2F‐4 appears to have an oncogenic role rather than a tumour suppressor role in breast carcinogenesis and, hence, it is not the gene targeted by 16q22.1 loss in breast carcinoma. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.This publication has 31 references indexed in Scilit:
- Loss of CD59 expression in breast tumours correlates with poor survivalThe Journal of Pathology, 2003
- Estimating the world cancer burden: Globocan 2000International Journal of Cancer, 2001
- Deregulated expression of DP1 induces epidermal proliferation and enhances skin carcinogenesisMolecular Carcinogenesis, 2001
- High-Resolution Integrated Map Encompassing the Breast Cancer Loss of Heterozygosity Region on Human Chromosome 16q22.1Genomics, 2000
- Genomic structure and mutation screening of theE2F4 gene in human tumorsInternational Journal of Cancer, 2000
- Expression of the E2F family in human gastrointestinal carcinomasInternational Journal of Cancer, 1999
- Mutations of the human E-cadherin (CDH1) geneHuman Mutation, 1998
- Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinomain situThe Journal of Pathology, 1997
- E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers.The EMBO Journal, 1995
- High frequency of allelic imbalance at chromosome region 16q22-23 in human breast cancer: Correlation with high pgr and low s phaseInternational Journal of Cancer, 1995